Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. - Wikidata - awgldk - TriplyDB

Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.

Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.

http://www.wikidata.org/entity/Q34094097

about

The RASopathies The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish Cardio-facio-cutaneous syndrome with precocious puberty, growth hormone deficiency and hyperprolactinemia Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.A cellular star atlas: using astrocytes from human pluripotent stem cells for disease studies Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.Costello Syndrome and Umbilical Ligament Rhabdomyosarcoma in Two Pediatric Patients: Case Reports and Review of the Literature.Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.Ras/MAPK syndromes and childhood hemato-oncological diseases.Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions.Recent advances in RASopathies.C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.Combinatorial Resistance: The Best Defense is a Good Offense.Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation.

P2860

Q27022142-A82DC1CC-6F61-4C31-9F71-B69F857A2ACD Q28512744-42755A5F-C57B-43A5-9E24-BBD0C3E8BD0E Q33778196-31B5A7C6-3E71-46D7-BAFB-EEBEB8BB9466 Q34149419-0234A611-EE0B-4A20-A701-A06B552EDF62 Q34660392-98213A0A-7BA1-4C27-901F-FAB638D50F22 Q36431974-44E3BB2C-8F91-4573-9308-269C7EAE461E Q36497139-F85CF95B-0F76-4AB6-AE16-72B83A9510C6 Q36682196-1F3F12F4-69E2-451A-B1A8-67573ED0C64B Q37463973-280C70CF-2AAD-44E9-B5B7-8367977524A5 Q37620212-48513992-FE55-4FEC-9296-83D965959057 Q37977296-FCC293B5-2D6D-4A1D-A2F8-449C09723563 Q38068387-BAE28161-B51C-4350-9092-638539CE6F24 Q38243763-A949075F-F9B8-44FB-8711-E909789D089F Q38601758-F0589C74-E047-459F-830A-8DBA89D3D1E0 Q39654702-64AF5369-C2DE-4CBF-B989-21349471E847 Q40290712-799C7300-CE43-4D4C-BCAC-413A7B92CF80 Q42909806-922F464C-99BA-491B-B98D-40EEB6AC3973 Q46083335-9CF2BF32-7305-444E-8A39-D137C22128C1

P2860

Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.

http://www.wikidata.org/entity/Q34094097

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@ast

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@en

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@nl

type

label

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@ast

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@en

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@nl

prefLabel

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@ast

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@en

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@nl

P1433

Q34094097-F26E42F5-5F9F-494E-B6D6-5A166485394F

P1476

Q34094097-C725376C-24D2-459A-BD1D-AFDB7ADB508D

P2093

Q34094097-0235972F-D115-485C-9223-5946C34DFB2D

Q34094097-1C087EDE-270F-42CC-9481-36ED48363080

Q34094097-24DB5F4C-564A-455A-8558-9E7C28905A1F

Q34094097-2E7DE0BE-BBE2-4370-BFCB-30B9A5B3E167

Q34094097-3FF1100A-38B8-4B1F-81C5-1254EE59F081

Q34094097-41C4F834-7B3C-497A-9F10-B3E5F3AFBDD8

Q34094097-41CCD8CB-4C5F-42E8-8E32-33BE45E8B6E9

Q34094097-529A716F-3C15-4E53-836F-BA0E17EB4F6A

Q34094097-54A9395B-B9C8-438D-B64A-771C1B8CC21B

Q34094097-8C996805-254E-42FF-AAF4-0219F6989F10

P2860

Q34094097-145CA6F4-6175-4AAC-A112-BF10139E9018

Q34094097-225781C6-627F-47A7-B261-40F3AF0A8C9D

Q34094097-27479B69-535E-4DF6-AD26-2B1F89025F79

Q34094097-300CA86D-A13D-4D77-96A0-DF6B65A2F3A1

Q34094097-322264FA-C637-483B-9824-EAB7652AB30D

Q34094097-46BC85A6-2D4C-4CFC-8F0C-80AC3B02F2D0

Q34094097-4AFD9BDC-B5C3-4387-8B22-0DF426AAB718

Q34094097-5021BD80-E445-4018-B563-407534F6ED55

Q34094097-5C26ACD2-CEF2-4311-A01D-C98044B6A38A

Q34094097-5ECF8662-D59B-4D09-AFF1-B22FB17D4F74

P304

Q34094097-3D87F77E-FA00-4EE7-82F4-A4D655FCEE45

P31

Q34094097-DD6A9E08-C846-4225-B81A-8063F7208166

P356

Q34094097-F51CF9D6-6540-44B7-816B-8026C9258462

P433

Q34094097-0E6121CF-9BF9-4212-83CF-D5D8CE69FF39

P478

Q34094097-563E21C7-7266-4780-9CEA-DAE7394A8F7F

P577

Q34094097-C5467B6E-E7A0-4D74-BEFC-2AE11DF2AD71

P698

Q34094097-00A4E000-D66E-4C80-8870-6D96291FE49C

P932

Q34094097-7C380388-638E-4880-8962-DB6C3B5DE11B

P356

P1433

American Journal of Medical Genetics Part C: Seminars in Medical Genetics

P1476

Costello and cardio-facio-cuta ...... linical trials in RASopathies.

@en

P2093

Anuradha Banerjee

http://www.w3.org/2001/XMLSchema#string

David H Viskochil

http://www.w3.org/2001/XMLSchema#string

Frank McCormick

http://www.w3.org/2001/XMLSchema#string

Jennifer O Lauchle

http://www.w3.org/2001/XMLSchema#string

Judith Sebolt-Leopold

http://www.w3.org/2001/XMLSchema#string

Katherine A Rauen

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

Pamela N Munster

http://www.w3.org/2001/XMLSchema#string

Roger J Packer

http://www.w3.org/2001/XMLSchema#string

Sorena Nadaf

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation

A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Advocacy groups as research organizations: the PXE International example

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

ras oncogenes in human cancer: a review

P304

136-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJMG.C.30294

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

157C

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21495172

http://www.w3.org/2001/XMLSchema#string

P932

4145816

http://www.w3.org/2001/XMLSchema#string